Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when UroGen Pharma Ltd. publishes a filing, an earnings call transcript or a press release.

Get URGN alerts

About Mark Schoenberg

The proxy statement of UroGen Pharma Ltd. reports total compensation of $1,170,640 for Mark Schoenberg in fiscal 2025, including a base salary of $369,607. Disclosed compensation is on record for 9 fiscal years. Mark Schoenberg has spoken on 4 earnings calls across 1 company, most recently for UroGen Pharma Ltd. on November 4, 2026. UroGen Pharma Ltd. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at UroGen Pharma Ltd. includes Elizabeth Barrett (CEO and Board Member), Arie Belldegrun (Chairman and Board Member), Chris Degnan (CFO) and 7 others.

Mark Schoenberg on recent calls

“I'd like to begin by building on Liz's discussion on how Zesturi adoption is evolving, particularly as physicians gain experience and increasingly incorporate the product into routine clinical practice.”
Other, UroGen Pharma Ltd. Q3 FY2026 Earnings Call ·
“Let me begin with the most recent update from the Phase 3 Envision trial. In May, we announced updated durability data from Envision with nearly three years of follow-up.”
Other, UroGen Pharma Ltd. Q2 FY2026 Earnings Call ·
“The American Urologic Association annual meeting will take place May 15th to 18th in Washington, D.C. Urogen will have a significant presence there, and we believe this is an important opportunity to engage with both community and academic urologists and further discuss the clinical value of Zesturi and Gelmito.”
Other, UroGen Pharma Ltd. Q1 FY2026 Earnings Call ·
“As a reminder, the Envision trial, which supported approval of CES-DURY, demonstrated an approximately 80% complete response rate at three months.”
Other, UroGen Pharma Ltd. Q4 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at UroGen Pharma Ltd.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 UroGen Pharma Ltd. (URGN) $369,607 $1,170,640
2024 UroGen Pharma Ltd. (URGN) $354,240 $878,885
2023 UroGen Pharma Ltd. (URGN) $341,469 $1,360,550
2022 UroGen Pharma Ltd. (URGN) $325,963 $599,610
2021 UroGen Pharma Ltd. (URGN) $284,907 $1,024,138
2020 UroGen Pharma Ltd. (URGN) $185,026 $948,458
2019 UroGen Pharma Ltd. (URGN) $205,000 $800,908
2018 UroGen Pharma Ltd. (URGN) $200,000 $300,000
2017 UroGen Pharma Ltd. (URGN) $13,636 $1,054,124

Recent activity